Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II

Trial Profile

A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 17 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pabinafusp alfa (Primary)
  • Indications Mucopolysaccharidosis II
  • Focus Registrational; Therapeutic Use
  • Sponsors JCR Pharmaceuticals
  • Most Recent Events

    • 15 Feb 2022 Results published in the JCR Pharmaceuticals Media Release.
    • 15 Feb 2022 According to a JCR Pharmaceuticals media release, data from this study was presented at 18th Annual WORLDSymposium.
    • 23 Mar 2021 According to a JCR Pharmaceuticals media release, the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). The approval is based on of evidence from non-clinical and clinical studies(including this and a phase II/III study).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top